Subject matters | Details | Categories |
---|---|---|
Health, Industry
|
An amendment to the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") regarding the right to appeal.
|
Regulation
|
Economic Development, Health, Industry, Intellectual Property, Research and Development, Science and Technology
|
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.
|
Policies or Program
|
Economic Development, Health, Industry, International Development
|
Canada-United States-Mexico Agreement (CUSMA) and pharmaceutical intellectual property protection.
|
Legislative Proposal, Bill or Resolution
|
Health, Industry
|
Canadian Drug Agency: Specifically, the mandate and creation of a new Canadian Drug Agency and transition work to support pharmacare-related initiatives.
|
Policies or Program, Legislative Proposal, Bill or Resolution
|
Health, Industry, Internal Trade
|
Communications regarding the maintenance of domestic supply of essential drug products.
|
Policies or Program
|
Economic Development, Health, Industry, Intellectual Property, International Trade
|
Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection.
|
Legislative Proposal, Bill or Resolution
|
Health
|
COVID-19: Regarding the development of a COVID-19 vaccine & policies and related to the COVID-19 pandemic.
|
Policies or Program
|
Health, Industry, International Trade
|
Health Canada's enforcement of Canada's Food and Drugs Act and Regulations as they relate to the cross border sale of drugs to the United States.
|
Legislative Proposal, Bill or Resolution
|
Health, Industry, Intellectual Property
|
Health Canada and the Patented Medicine Prices Review Board(PMPRB) regulatory implementation and specifically, pharmaceutical pricing policy issues arising from the Patented Medicine Regulations.
|
Regulation, Policies or Program
|
Economic Development, Health, Industry
|
Incentives and programs to attract and support manufacturing activities in Canada
|
Policies or Program
|
Economic Development, Health, Industry, Research and Development, Science and Technology, Taxation and Finance
|
Input into the Patented Medicines Price Review Board evaluation of annual R&D investments by companies in Canada based on Scientific Research and Experimental Development (SR&ED) tax rules. Working with PMPRB and legislators to ensure appropriate measures of R&D investment are in place.
|
Policies or Program
|
Health, Industry
|
Modernization of Food & Drug Act: support for proposed regulatory changes, modernization and international harmonizations with other regulatory bodies (European Medicines Agency/U.S. Food and Drug Administration).
|
Regulation
|
Health
|
Proposed national pharmacare: Specifically, government’s intention to introduce a national pharmacare program.
|
Legislative Proposal, Bill or Resolution, Policies or Program
|
Health, Industry, Intellectual Property, Research and Development
|
Research and Development (R&D): Input on Canada's clinical trial approval and implementations processes; Investing in Canada in R&D.
|
Legislative Proposal, Bill or Resolution, Regulation, Policies or Program
|
Health, Industry
|
Subsequent Entry Biologics (SEBs): the need for regulatory amendments to facilitate their approval.
|
Regulation
|
Janssen Inc. is a subsidiary of US based Johnson & Johnson and is bio pharmaceutical company focused on the sales, marketing and distribution of innovative medicines. Janssen Inc. has no subsidiary companies, although another entity, Johnson & Johnson (Canada) Inc., which is also registered to lobby federally, may have a direct interest in its lobbying.
Berkeley Vincent, President
Address:
19 Green Belt Drive
Toronto, ON M3C 1L9
Canada
Telephone number:
416-382-4856
Janssen Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
This is the responsible officer name as provided in the most recent registration for the corporation or organization.
Name | From | To |
---|---|---|
Janssen Inc./ | 2024-04-01 | current |
Janssen Inc./ | 2010-12-13 | 2024-04-01 |
Janssen Ortho Inc | 2008-08-01 | 2010-12-13 |
Responsible Officer Name | From (YYYY-MM-DD) | To (YYYY-MM-DD) |
---|---|---|
Berkeley Vincent | 2022-11-01 | Current |
Alaine Grand | 2022-07-23 | 2022-11-01 |
Jorge Bartolome | 2019-09-03 | 2022-07-23 |
Chris Halyk | 2006-12-18 | 2019-09-03 |
Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.
Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.
Results below are sorted by posted date, beginning with the most recent.
Registrants are required to submit a monthly communication report for each oral and arranged communication with a designated public office holder. The name of the most senior paid officer (i.e. the registrant) will appear on all in-house monthly communication reports, whether or not he/she participated in the communication.
Note: Monthly Communication Reports are due on the 15th day of each month for communications that took place in the previous month.
Results below are sorted by posted date, beginning with the most recent.
Position | Period Held | Last Date Designated Public Office Held |
---|---|---|
Director of Parliamentary Affairs/Executive Assistant to the Leader of the Opposition
House of Commons, Office of the Leader of the Opposition |
July 2009 to May 2010 | May 31, 2010 |
Executive Assistant to the Prime Minister
Prime Minister's Office, PMO |
December 2003 to February 2006 | Not a designated office |
Legislative Assistant to the Minister of Finance
Finance Canada, Office of the Minister of Finance |
January 2000 to June 2002 | Not a designated office |
Position | Period Held | Last Date Designated Public Office Held |
---|---|---|
Director of Parliamentary Affairs/Executive Assistant to the Leader of the Opposition
House of Commons, Office of the Leader of the Opposition |
July 2009 to May 2010 | May 31, 2010 |
Executive Assistant to the Prime Minister
Prime Minister's Office, PMO |
December 2003 to February 2006 | Not a designated office |
Legislative Assistant to the Minister of Finance
Finance Canada, Office of the Minister of Finance |
January 2000 to June 2002 | Not a designated office |